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ABSTRACT 
Effects of Combined Bevacizumab and Paclitaxel on Tumor Interstitial Fluid Pressure in a 
Preclinical Breast Cancer Model 
by 
Ricardo H. Alvarez 
Several mechanisms of cell resistance are often accountable for unsuccessful chemotherapy against 
cancer. Another reason, which has received increased attention, is the inefficient transport of 
anticancer drugs into tumor tissue. These impaired transports of chemotherapy into the tumor have 
been attributed to abnormal microvasculature and to pathologically increased tumor hypertension also 
called: interstitial fluid pressure (IFP). The pathophysiological processes leading to elevated tumor 
IFP are poorly understood. Here, in a preclinical breast cancer model, it is argued that a condition of 
raised IFP is a major factor in preventing optimal access of systemically administered chemotherapy 
agents. In our experimental model, we used a GILM2 human breast cancer in xenografts; mice were 
treated with different doses of paclitaxel –a widely used antimicrotubular agent, and bevacizumab –
monoclonal antibody against vascular endothelial growth factor (VEGF). The proposed research 
project is designed to test the hypothesis that paclitaxel in combination with bevacizumab decreases 
the tumor IPF by restoring tumor permeability and increasing chemotherapy delivery. We 
demonstrated that the combination of paclitaxel and bevacizumab produced greater tumor control 
than either agent given alone and this combination reduced the IFP, producing an increment of 75% 
of apoptosis compared with the control arm. In addition, the intra-tumor paclitaxel quantification by 
liquid chromatography/Mass Spectrometry (LC/MS) demonstrated that lower dose of both agents 
showed a synergistic effect compared with high dose of treatment, where there is no significantly 
increase of paclitaxel into the tumor. These preclinical results are likely to have broad implications 
for the utility of anti-angiogenic therapies alone and in combination with chemotherapeutic agents.  
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Chapter 1 
1. Introduction: Breast Cancer 2010 
In the United States, breast cancer is the most commonly diagnosed cancer and is the second 
leading cause of death in women. [1] It is estimated that 207,090 new patients of breast cancer 
will be diagnosed in the United States in 2010 representing 28% of all female cancers 
incidence, and 39,840 deaths representing 15% of all female cancer death. [2] Breast cancer is 
also an important public health problem in the world; in 2007, 1.3 million women were 
diagnosed with breast cancer worldwide, and almost 465,000 died from the disease. [3] Over 
the past few years, breast cancer mortality has been steadily decreasing due to a variety of 
reasons, including success of mammography screening and the availability of newer 
cytotoxic chemotherapy and targeted agents. [4, 5] 
The treatment of MBC is palliative and rarely curative. Therefore, the goals of the 
treatment consist in alleviation of symptoms and improvement or maintenance of good 
quality of life. This has led to much interest in the understanding of the pathogenesis of 
breast cancer metastasis and the mechanism of tumor resistance. 
Although the use of anthracyclines and taxanes has led to an increase in survival of 
patients with metastatic or locally advanced disease, the benefit from third-line therapies is 
less clear. Patients who have disease that is resistant to these therapies, or who develop 
toxicities causing cessation, may then receive other agents that are of limited benefit. 
Although there is no widely accepted standard of care, current options for patients that who 
failed anthracyclines and taxanes include the vinca alkaloids, [6, 7] gemcitabine, [8] 
capecitabine, [9, 10] nanoparticle albumin-bound paclitaxel, [11] and recently, ixabepilone  [12-15] 
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The principal cause of death from cancer is metastases that are resistant to 
conventional therapies. Approximately, 1 out of 5 patients with diagnosis a of breast cancer 
will develop metastasis in 5 years. [16] The prognosis of patients with metastatic breast cancer 
remains poor; the 5-year survival rate is only 26% in the United States. [17] 
Because of the lack of clinical responses to anti-VEGF treatment in solid tumors, with 
the exception of renal cell and hepatocellular carcinoma, several investigators started 
combining anti-VEGF treatments with conventional cytotoxic drugs. With this combination, 
the aim is to target two compartments: the stroma and endothelial cells and the cancer cells. 
Currently, in the United States, the Food and Drug Agency approved in three of the 
most common solid tumors -breast, lung and colorectal cancer- the combination of anti-
VEGF (bevacizumab) in combination with chemotherapy as front-line treatment for 
advanced disease.  
 
2. Mechanism of Resistance to Cancer Treatment 
One of the principal factors responsible for failure to respond to cancer treatment is drug 
resistance. There are two types of tumor resistance: a) intrinsic resistance to de novo 
treatment with chemotherapy, and b) secondary or acquired resistance, for the cases when 
tumor initially responded to treatment and became resistant during, or right after treatment. 
[18] Drug resistance, whether intrinsic or acquired, is believed to cause treatment failure in 
over 90% of patients with metastatic cancer, and resistant micrometastatic tumor cells may 
also reduce the effectiveness of chemotherapy in the adjuvant setting. [19] Clearly, if drug 
resistance could be overcome, the impact on survival of the cancer patient would be highly 
significant. 
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There are many factors that affect drug sensitivity. These include mechanisms such as 
those that limit the amount of drug reaching the tumors and those affecting the tumor 
microenvironment. [18] The classical description of cellular mechanisms of resistance involve 
multiple processes, including: drug influx and efflux, drug inactivation, drug targets, DNA 
damage repair, cell cycle arrest versus apoptosis, induction of apoptosis, and pro-survival 
signaling. [20] 
 
3. Tumor Microenvironment 
More than a century ago, Stephen Paget, a British surgeon, proposed that the 
microenvironment of a developing tumor is a crucial regulator of carcinogenesis and he 
elaborated his famous “seed and soil” hypothesis. [21] He hypothesized that cancer cells (the 
seeds) were interconnected by several types of signals with the stroma cells (the soil). After 
reviewed 735 autopsies of patients with breast cancer in 1889, he concluded that the pattern 
of metastasis is not a random process, instead was a complex and regulated process which 
depends on the tumor stroma. This seminal observation was demonstrated a century later 
with multiple experiments. [22] 
An influential publication by Dr. Dvorak in 1986, clearly showed that the growth of 
carcinomas beyond a diameter of about 1-2 mm requires the formation of a supporting tumor 
stroma to ensure the supply of nutrients for tumor cell survival and growth. [23] The tumor 
stroma microenvironment may differ between tumor types and disease stages. Tumor stroma 
represents between 20% to 50% of the mass in breast, lung, and colorectal carcinomas. 
However, in tumors with extensive desmoplastic component, the stroma can represent 90% 
of the mass of tumor.  
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It is important to mention that the mass and composition of the stroma differs 
between tumors and is not related with the degree of tumor malignancy. [24]  
The tumor stroma is composed of a variety of cells which are interconnected by 
several types of cross-talk signaling. The most common resident cell types are fibroblast, 
smooth muscle cells, immune and inflammatory cells, lipocytes and endothelial cells. [25] The 
active interconnections between cancer cells and the tumor stroma are responsible in part for 
the strong influences that stroma cells impose on cancer cells. The traditional concept that 
cells immediately adjacent to a tumor are passive structural elements that elicit an immune 
response in an attempt to resist and reject the tumor has now been challenged by a 
considerable body of evidence from many investigators.[26] So, it is becoming apparent that 
the tumor microenvironment exerts an important role in the neoplastic phenotype. 
In order to maintain a tissue homeostasis, all tissues require an extracellular network 
to provide structural support and facilitate the cell-cell communication. The 
microenvironment of solid tumors has several characteristics that distinguish it from the 
corresponding normal tissue. These characteristics are thought to become established due to 
an abnormal relationship between poorly formed tumor vasculature and the physiologic 
characteristics of the cells within the tumor. [27] In order to obtain nutrients for their growth 
and metastatic potential, cancer cells will utilize the host blood vessels, sprout new vessels 
from existing ones (angiogenesis), and recruit endothelial cells from the bone marrow 
(postnatal vasculogenesis). [28] The anomalous morphology of blood vessels is responsible for 
the irregular blood flow which results in chaotic blood vessel networks. This interaction 
between abnormal blood vessels and cancer cells is responsible for the microenvironmental 
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hallmarks of solid tumors consisting of: low oxygen tension or hypoxia, low extracellular pH 
or acidosis, and high interstitial fluid pressure. [19] The relationship between abnormal blood 
vessels, hypoxia and is depicted in Figure 1. 
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Figure 1: Microenvironment Conditions of the Tumor Present Barriers to Therapy.  
Confocal micrographs from tumor section of human breast cancer xenograft. Blood vessels 
stained for CD31 (red), pericytes for desmin (green), and hypoxia for HypoxyProbe 
(brown) 
a) The tumor microenvironment is typically hypoxic with chaotic vasculature with unstable 
endothelium, loose pericytes, and leaky vessels. Poor oxygen delivery by the defective 
vasculature and oxygen consumption by the tumor cells results in hypoxic areas. In addition, 
the hyperpermeable blood vessels produce a hypertensive extracellular matrix (ECM); Dark 
brown color represents tissue hypoxia stained with HypoxyProbe. 
 (b) Relationship between abnormal blood vessels and pericytes. Dual immunofluorescence 
staining for CD31 (red) and desmin (green) was performed to visualize endothelial cells and 
pericytes, respectively. The white rectangle shows the process of “sprouting angiogenesis”. 
Endothelial sprouts tipped by filopodia are abundant on blood vessels and are currently 
known as a molecular target for the anti-VEGF treatments. Sprouting angiogenesis is 
characterized by non-mitotic endothelial cell activity, high reversibility, and is always 
accompanied by pericytes.  
Images were taken by the author of this thesis at the Cancer Biology Department at 
original magnification x400 and x100 respectively. 
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Figure 1 
a. Tumor Microenvironment. Relationship between endothelial cells (red), pericytes 
(green) and tissue hypoxia (dark brown). 
Hypoxia
Hypoxia
Hypoxia
CD31
Desmin
 
b. Tumor Blood Vessels: Endothelial Cells and Pericytes. 
 
Endothelial cells:  CD31
Pericytes:  Desmin
Tumor cells: Hoechst
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These physiological characteristics of tumor microenvironment have been shown to act as an 
impressive obstacle to the delivery and efficacy of cancer therapy. Novel molecular strategies 
designed to understand the correct structure and function of tumor vessels and how to 
interfere with these physiological barriers will improve cancer treatment. 
 
4. Stromal Microenvironment as Cause of Drug Resistance 
In order for an anticancer agent to be therapeutically effective, it should be uniformly 
distributed through the tumor circulation, cross the vessel wall, and pass through the ECM 
and finally arrive in the stroma and cancer cells with adequate concentration to cause tumor 
cell lethality.  
Drug resistance remains a principal problem impeding the success of chemotherapy 
in the treatment of cancer. [29] Currently, most of the cancers that are treated with 
conventional anticancer therapies become resistant to these agents. Two important 
mechanism of resistance have been identified including intrinsic and acquired resistance. [18] 
Intrinsic resistance to anticancer drugs, or resistance developed during chemotherapy, 
remains a major obstacle to successful treatment. In the current literature a large number of 
published studies about resistance of cancers to chemotherapy focus on cellular and genetic 
mechanisms as principal factors of resistance, whereas very few describe the role of 
microenvironment factors. [30] 
There is a generally accepted hypothesis that tumor cells are genetically unstable and 
can mutate and that drug resistance of human tumors arises because of the selection of 
mutant drug-resistant cell during tumor progression, or following exposure to chemotherapy. 
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This resistance in the clinic manifests itself as lack of initial response –mentioned as 
refractoriness, or as regrowth after initial response (relapse). 
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Chapter 2 
1. Physiological Barriers of Drug Resistance 
The tumor microenvironment possesses several properties that distinguish it from the normal 
tissues. These differences arise from the irregular characteristics of the blood vessels and the 
physiologic properties of the cells within the tumor. [27] The tumor microenvironment has 
been recently recognized as a physiological barrier to conventional chemotherapy and 
radiation-based therapies. These barriers include, tumor hypoxia, tumor acidity (low pH), and 
high tumor IFP. (Figure 2) 
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Figure 2 - Tumor acidosis and Hypoxia 
a) Diagrammatic representation of tumor cells and the extracellular matrix surrounding a 
capillary.  
b) Schematic representation of the gradient of oxygen concentration (pO2; dashed line) and 
pH (dotted line) in relation to nearest tumor blood vessel.  
Graphic obtained with permission from Tedran and collaborators. [29] 
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Figure 2 - Tumor Acidosis and Hypoxia  
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Tumor Hypoxia 
Tumor hypoxia is a universal feature of solid tumors. In contrast to normal tissue, the tumor 
blood vessels are characterized by the utilization of oxygen which is larger than the oxygen 
release. [31, 32] This imbalance is responsible for inconsistent tissue perfusion, producing high 
variation of oxygen concentration throughout the tumor mass. Two main causes of tumor 
hypoxia have been recognized: permanent limitations in oxygen diffusion results in chronic 
hypoxia, and transient limitations in blood perfusion result in acute hypoxia.[32] More 
importantly, most of the assays of tumor hypoxia currently available do not distinguish 
between chronic and acute hypoxia. From the clinical point of view, tumor hypoxia has been 
implicated in the resistance to treatment, especially radiation therapy. In addition, hypoxia is 
also responsible for malignant phenotype, and is predictive of metastasis and poor outcome 
in a variety of tumor types. [33-35] 
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates multiple 
genes that are responsible for the adaption of cells to live in normoxia (~21% O2) to hypoxia 
(~1% O2) conditions. [36, 37] Since the discovery of HIF, more than 2 decades ago, the 
knowledge of the role of HIF in tumor biology has grown exponentially. Because the broad 
spectrum of influences of HIF-1, it is actually considered an important target for many 
tumors. In a very elegant publication, Cairns et al [38] using RKO and Su.86 cell lines as 
preclinical models demonstrated that blocking the HIF-1 pathway represented a novel 
microenvironment target for solid tumors. In a retrospective review of 150 patients with early 
invasive breast cancer, treated between 1985 and 1993 in Holland, HIF-1 alpha expression 
correlated with multiple clinicopathologic variables. [39] The results showed that a high level 
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of HIF-1 alpha was associated independently with shortened disease free survival (p = 0.004) 
and overall survival (p = 0.008) in patients with lymph node negative breast cancer. 
 
Tumor Acidosis 
The microenvironment tumor acidosis (pHe) is low compared with the normal tissues. 
Initially it was thought that the tumor acidosis was the result of accumulation of lactate, the 
product of anaerobic glycolysis associated with tumor cells. Many of the anti-neoplastic 
chemotherapy drugs used commonly for cancer treatment are influenced by the 
microenvironment acidity. In general, the diffusion of drugs into cells occurs by passive 
diffusion when they are uncharged. However, when drugs are highly polar with acidic or 
basic groups the cellular uptake depends on the pHe. Thus, basic drugs like doxorubicin, 
mitoxantrone, and vinblastine have reduced activity in a low pHe due to decreased drug 
uptake. 
In the past, preclinical studies using direct measurement of the pH within tumor 
models with electrode-based techniques showed that tumor cells can carry out glycolysis and 
produce lactate are still able to generate an acidic environment. [40, 41] Using more modern 
techniques with 31P magnetic resonance spectroscopy to measure the characteristics of pH-
dependent microenvironment in solid tumors, it was determined that the acidity within the 
tumor is a combination of the pHe and the internal, intracellular pH (pHi). Cells within the 
tumor are capable of maintaining a reasonably neutral cytosolic pH in the face of external 
acidosis. [42] 
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Chapter 3 
1. Interstitial Fluid Pressure and Transvascular Transport 
The interstitium 
New strategies to improve the distribution of drugs between normal and tumor tissues that 
reduce toxicities associated with chemotherapy regimens for solid tumors in conjunction with 
increase efficacy are warranted. A potential target is tumor IFP. 
The ECM or interstitium consists of the collective spaces between cells, and accounts 
for approximately one sixth of the total body volume. [43] The extracellular compartment is 
composed of a collagen fiber scaffold that contains a gel phase made up of hyaluronan, 
glycosaminoglycans (GAGs), salts, and plasma-derived proteins. [43] The collagen structure is 
thought to physically restrain the intrinsic tendency of the hyaluronan and the 
glycosaminoglycans to swell, thus reaching equilibrium.  [44, 45] 
Interstitial fluid, made up of water and solutes, acts as the transport medium for the 
exchange of nutrients, waste products, and oxygen. IFP is the result of oncotic pressure in the 
interstitial space, oncotic and hydrostatic pressures in the microvascular space, the reflection 
coefficient, and the hydraulic conductivity of the vascular wall and interstitial space. 
Together these forces determine the net filtration pressure across the capillary plasma 
membrane and are determined by the Starling equation: [46] 
Jv = Kf [(Pc-Pif) - σ(COPc-COPif)], 
Where fluid transport across the capillary wall can be described quantitatively, Jv is net 
capillary fluid filtration, Kf is the capillary filtration coefficient, Pc and Pif are the hydrostatic 
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pressures in capillary and interstitium, respectively, COPc and COPif are the corresponding 
colloid osmotic pressures, and σ is the capillary reflection coefficient for proteins.  
This traditional concept of transcapillary fluid flux is the product of the pressure 
imbalance across the capillary wall, and does not include cells in the regulation of 
interstitium. A new concept in the interstitium fluid regulation included connective tissue 
cells that are not organ specific but are an integral part of the extracellular matrix. (Figure 3) 
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Figure 3: Overview of the transcapillary-interstitial fluid exchange system.  
The transcapillary hydrostatic (P) and colloid osmotic pressure (COP) determines capillary 
fluid flux. Subscripts “c” and “if” denote plasma and capillary reflection coefficient, 
respectively. The capillary net filtration pressure is normally 0.5 to 1 mmHg and results in a 
net fluid filtration (Jv) that is removed by lymph flow. Collagen and hyaluronan are abundant 
structural component of loose connective tissues. Graphic obtained with permission from 
Wiig and collaborators. [45] 
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Figure 3 - Overview of the transcapillary-interstitial fluid exchange system 
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Regulation of the IFP 
The normal tissues possess a very sensitive regulation of ECM fluid. For instance, in most 
tissues of the body, the IFP under normal conditions is slightly negative, e.g. about -1 mmHg 
in the skin. However, under pathological conditions, such as burn injuries, urticaria or 
inflammation, the net filtration pressure increases tremendously due to a fall in the IFP to as 
low as -150 mmHg, resulting in edema formation. [47] This example illustrates that there is 
also an active control of the transcapillary exchange of fluids by the interstitium. Moreover, it 
also implies that cells in the interstitial compartment, e.g. fibroblasts, and pericytes are 
important regulators of the IFP. One possibility for the cells in the connective tissues to exert 
a controlling force over the IFP is via the contacts made between the cell and ECM 
constituents through integrins. [44] Another possibility is related to the mesodermal origin of 
such cells and the contraction capacity eliciting changes in the ECM. 
IFP is Elevated in Solid Tumors 
The clinical measurement of IFP in normal subcutaneous tissues and muscle tissues show a 
range from -2 to 4 mm Hg. [48, 49] In contrast, solid tumors have elevated IFP compared with 
normal tissue, with a steep rise in pressure starting at the periphery of the tumor. Interstitial 
pressure was first noted to be elevated in animal tumors in 1950 by Young and colleagues, 
[50] and the first data on interstitial tumor pressure in humans were published in 1990. [51, 52] 
These studies suggest that many human tumor nodules have interstitial pressures much 
greater than in normal tissues. The precise cause of increased tumor IFP is not well 
understood: a number of mechanisms have been hypothesized, yet none experimentally 
confirmed. Explanations included scarcity of lymphatic vessels, tumor fibrosis, and the leaky 
nature of tumor vessels, caused by an increased signaling from vascular endothelial growth 
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factor receptor. [53] Implantation of the same tumor cell line at diverse sites in mice produces 
dissimilar IFPs, suggesting that the microenvironment impacts tumor IFP. [54] Nowadays, we 
accept that the cause of high tumor IFP is multifactorial. 
Consequences of Elevated IFP 
Elevated IFP in tumors is a consequence of severe microvascular, lymphatic, and interstitial 
abnormalities. In accordance with an increased IFP, the oncotic pressure of tumor interstitial 
fluid is also elevated compared to normal tissue and is close to that of plasma, indicating that 
there is a reduced transport of fluids into tumors compared with normal tissues. [55] This 
could affect the distribution of therapeutic antibodies into tumors because macromolecules 
are thought to be transported preferentially through convection. However, a high tumor IFP 
could also conceivably hinder the delivery of low molecular weight compounds, which are 
thought to be transported mainly by diffusion in normal tissue. The microvascular exchange 
barrier in tumors is nonselective, because of its leaky nature, and thereby favors convective 
transport of water-soluble low molecular weight agents. Also, the increased water content in 
tumors may facilitate diffusion of molecules through the tumor interstitium. [56] Indeed, 
studies in experimental models have shown that lowering tumor IFP, either by 
pharmacologic interference or by increasing the transcapillary hydrostatic pressure gradient, 
is paralleled by an increased transport of both macromolecules and low molecular weight 
compounds. [56, 57] Local delivery of prostaglandin E1 to tumors in rats lowered the IFP and 
enhanced the penetration of 51Cr-EDTA. [56] Targeted delivery of tumor necrosis factor-α to 
tumor vessels in mice enhanced the penetration of doxorubicin into tumors.  [57] 
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In a series of patients with cervical carcinoma there was a correlation between 
interstitial pressure and the oxygenation status of the tumor and an inverse correlation with 
tumor response to radiation therapy. [58]  In another study in patients with cervical cancer, 
tumor IFP was a strongly independent prognostic marker for radiation therapy of cervical 
cancer. [59] In this study, 102 eligible patients with locally advanced cervical cancer were 
evaluated during treatment with radiation therapy. The IFP assessment was done using a 
wick-in-needle technique. Patients with high IFP were more likely to recur both locally and 
at distant sites. In addition, patients with high IFP were significantly more likely than those 
with low IFP to recur after radiotherapy and die of progressive disease. 
Role of Platelet-Derived Growth Factor Receptor in tumor IFP Regulation 
Platelet-derived growth factor (PDGF) is a mitogen and a chemoattractant for cells of 
mesenchymal origin, e.g. fibroblasts and smooth muscle cells, which acts by binding two 
structurally related tyrosine kinase receptors. Different roles in the paracrine stimulation of 
tumor stroma have been described for PDGF. [60] 
The well-documented PDGF β-receptor expression in the stromal compartment in 
many common solid tumors (lung, breast, colon), which also are characterized by tumor 
interstitial hypertension, is consistent with a role of PDGF β-receptors in the control of tumor 
IFP. [61] The tyrosine kinase inhibitor imatinib inhibits the kinase activities of the PDGF 
receptors, c-Kit, ABL, and ARG with similar potencies. [62] Imatinib –a potent inhibitor of 
BCR/ABL oncoprotein and c-Kit receptor- is currently used in the treatment of chronic 
myelogenous leukemia and gastrointestinal stromal tumors. Three preclinical studies have 
examined the effect of imatinib on the IFP in experimental tumor models, [63-65] and analyzed 
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in a separate publication. [66] The first of these studies found that rats with colonic carcinomas 
treated with imatinib exhibited a reduced IFP measured by the wick-in-needle technique. 
Treated tumors showed a mean IFP of 11.3 +/- 1.1 mm Hg, whereas untreated tumors 
displayed a mean IFP of 16.8 +/- 0.9 mm Hg (p < 0.01). Subsequently treatment with 
imatinib increased the uptake of freely diffusible tracer 51Cr-EDTA into the tumors (p < 0.05) 
compared with untreated animals. [63] The second study in mice showed that imatinib induced 
lowering of IFP was paralleled by an enhanced tumor content of paclitaxel. [64] Mice with 
KAT-4 tumors were injected with [3H] paclitaxel and radioactivity was measured 8 or 24 
hours. Mice treated with imatinib significantly increased tumor uptake of [3H] paclitaxel 
compared with the control group (p < 0.05). Imatinib had no direct effect on tumor growth, 
but the combination of imatinib and paclitaxel, increased the efficacy of chemotherapy. In 
the third study, mice injected with human thyroid carcinomas were treated with various doses 
of the epothilone B (EPO906 or patupilone a novel anti-microtubular agent), alone or in 
combination with imatinib. [65] The combination was more effective than chemotherapy 
alone, and tumors treated with the combination were more than 40% smaller. In addition, 
there was a tumor-specific, three-fold increase in tumor level of EPO906. Interestingly, 
various treatment regimens of imatinib showed a correlation between the ability of the 
treatment to lower tumor IFP and enhanced tumor uptake and efficacy of EPO906.  
These studies clearly establish that inhibition of PDGF receptor signaling is a novel 
strategy for enhancement of chemotherapeutic effects on solid tumors. These data also 
suggest that the reduction of tumor IFP is related to the drug uptake and is one of the 
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mechanisms of tumor sensitivity. There are currently several clinical trials in advanced solid 
tumors, exploring the combination of standard chemotherapy with imatinib. 
IFP and transvascular transport in tumors 
Extravasation of materials from the blood vessels can occur by diffusion and convection and 
is described by the following equation: [67] 
J = PS (Cp - Ci) + Lp S) 1-σ) [(Pv  - pi) - σ (πv - πi)] Cp 
J is the flux (mass per unit volume) of materials crossing the vessel wall, P is the vascular 
permeability, S is the vessels’ surface area, Cp – Ci is the concentration difference of the 
material between the plasma and the interstitial space, Lp is the hydraulic conductivity of the 
vessel wall, Pv – pi is the difference between microvascular and IFP, σ is the osmotic 
reflection coefficient, and πv - πI is the osmotic pressure difference across the wall. The 
vascular permeability depends on the properties of the particle (size, charge and 
configuration) and the vessel wall (pore size, charge and arrangement). It decreases as the 
particle size increases and becomes zero when the particle size is larger than the pore cut-off 
size. The hydraulic conductivity is a property of the morphology of the wall surface occupied 
by pores.  
Young and collaborators, showing that the “tissue pressure” of testicular tumors is 
substantially higher than in normal tissue, did the first preclinical tumor IFP assessment. [50] 
Since then, multiple other investigators have demonstrated that the IFP of most, if not all, 
experimental and clinical tumors is elevated. [68] During the last four decades multiple 
investigators have measured tumor IFP in several tumor types. For instance, pressures of up 
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to 60 mmHg were found in melanomas [69-71] and the mean IFP of head and neck carcinomas 
was shown in a large number of patients to be 19 mmHg. [52] Still, the etiology of tumor IFP 
is unclear, the tumor microvascular pressure has been found to correlate with the IFP. [69] 
This evidence support the concept that the stromal compartment is likely to be an important 
determinant of tumor IFP, since implantation of the same tumor cell line at diverse sites gives 
rise to dissimilar absolute pressures. [54] 
One of the consequences of the high IFP in tumor tissue has been proposed to be an 
impaired transvascular transport of fluids and molecules into the tumor interstitium. [60] 
Several investigators demonstrated that the tumor interstitium has unique biophysical 
properties provide experimental support for this proposal. [72, 73] 
Many investigators have used pharmacological intervention to lower the tumor IFP as 
a viable strategy to increase the uptake of anti-cancer drugs into tumors, thereby achieving 
higher quantities of effective treatment into the tumor. Several agents administered either 
locally or systemically, have been shown to alleviate the interstitial hypertension in the 
experimental setting. Various substances, such as nicotinamide and a bradykinin B2 agonist, 
act on the microvasculature, whereas others, such as hyaluronidase, affect the 
microenvironment. It is notable, however, that the precise mechanism of action in most 
treatments is not well understood. 
Tumor Angiogenesis and Interstitial Hypertension 
The growth of neoplastic cells in a confined and stiff interstitial matrix can induce solid 
stress, causing an increase in microvascular pressure (MVP) and IFP. The MVP is dependent 
on arteriovenous pressure differences and the geometric and viscous resistance to blood 
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flows. Boucher, et al, hypothesized that MVP is a major determinant of IFP due to the high 
permeability of tumor vessel and the lack of functional lymphatics. [69, 74] The same group of 
investigators [75] reported that taxanes inhibit the growth of murine mammary carcinoma 
(MCa-IV) and the human soft tissue sarcoma (HSTS-26T). After treatment with paclitaxel 
blood vessels were measured at 48 and 96 hours, demonstrating that the diameter increased 
significantly. The increase of vascular diameter was associated with reductions in MVP and 
IFP. Thus, taxanes might be responsible for the increase of delivery of therapeutic agents into 
the tumor. [76] 
VEGF is a potent angiogenic factor released by a variety of normal and neoplastic 
cells following a hypoxic stimulus. VEGF was originally discovered as a vascular 
permeability factor (VPF) a glycoprotein secreted by tumor cells that potently stimulates 
ascites formation and vascular leak.[77] This vascular leak, most probably contributes to the 
elevated interstitial pressure of ECM commonly seen in solid tumors. A recent report showed 
that blocking the VEGF signaling by a VEGF-receptor-2 antibody decreases the IFP in a 
variety of tumor models, not by restoring the lymphatic function, but by producing a 
morphologically and functionally normalized vascular network. [78] The same investigators 
also report that an anti-VEGF antibody can lower IFP in rectal carcinomas in patients. [79] 
Thus, this process of “vascular normalization” might be responsible for the increase of 
survival rates in animal studies and for the efficacy demonstrated with patients with rectal 
cancer after treatment with combination of bevacizumab and cytotoxic chemotherapy.  
One of the main functions of pericytes consists in providing stability of blood vessels. 
It is also critical in the development of microvessels in many organs. Pericytes –as well as 
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endothelial cells, are also sensitive to anti-VEGF treatments. A recent study demonstrated 
that pericyte density is affected by anti-VEGF therapies. [80] Therapeutic benefits were 
recently observed after combination of the VEGF antagonist with imatinib in a genetic model 
of insulinomas, presumably through imatinib-mediated targeting of PDGF receptors on 
pericytes.  [81] This study also provided evidence of the important role of PDGF-BB and 
PDGF-DD in pericyte recruitment to tumors. Together, these observations suggest that 
pericytes represent an important target for the anti-VEGF treatment.  
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Chapter 4 
Investigation of Tumor IFP in a Xenograft Breast Cancer Model 
The fact that most solid tumors possess a high interstitial tumor pressure, led us to propose 
that tumor hypertension can be responsible for the tumor drug uptake which might be 
responsible of tumor efficacy. Using a xenograft tumor model, we set out to investigate the 
effect of tumor IFP using two doses of paclitaxel and bevacizumab, analyzing the efficacy of 
the combination of anticancer drugs and transvascular drug transport.  
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Material and Methods 
Cell Line 
Dr. Janet E. Price provided the GILM2 cell line. This cell line was originated from GI101A 
human breast cancer cell line initially provided by Goodwin Institute for Cancer Research, 
Inc. (Plantation, Florida) [82] Lung metastasis-derived lines were established as follows; the 
lung from mice injected with GI101A cells were minced finely and plated in culture dishes. 
The resulting culture was named GILM1. This cell line was expanded in culture and injected 
into mice. Metastases in the lungs of these animals were isolated and the procedure repeated 
to produce the line GILM2 (a pool from the metastases of three mice). [83] This new cell line 
demonstrated a higher anchorage-independent growth, tumorigenicity and spontaneous lung 
metastasis than GI101A cells. [84] 
For the experiments in vitro, we seeded 2 x 106 cells/ml and cells were maintained in 
monolayer culture in Dulbecco’s minimum essential medium-F12 medium (DMEM/F12) 
supplemented with 10% FBS, L-glutamine, 5% v/v insulin-selenium-transferrin supplement 
(Sigma Chemical Co., St Louis, Missouri). Actual cell numbers were calculated by 
multiplying diluted times compared with initial cell numbers. Cell viability % = viable cell 
numbers/total (viable + dead) cells numbers x 100%. Inhibition % = (control groups-
experimental groups)/control groups for viable cell numbers x 100%. Differentiation was 
evaluated by nitroblue tetrazolium (NBT, Sigma) reduction test. 
To determine the in vitro tumor growth inhibition of GILM2 cells by the reagents, 
cells were cultured in monolayer culture. GILM2 cells were plated in 96-well culture plates 
at an initial density of 5 x 103 cells per well, and allowed to attach for 24 h.  The culture 
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medium was then changed and the cells were incubated for a further 72 hr in different culture 
conditions: medium alone, with paclitaxel (1 - 10 nM), with bevacizumab (0.1 - 10 ug/ml) or 
a combination of these agents.  Relative cell numbers were determined using MTT.  Aliquots 
of 40 ul of a 5 ug/ml solution of MTT were added to each well and incubated for 2hr; the 
medium was then aspirated and the cells lysed by the addition of 100 ul DMSO.  The 
conversion of MTT to formazan in metabolically viable cells was monitored with a MR-5000 
microtiter plate reader to read at 570 nm  (Dynatech, Inc Chantilly, VA).  All assays were 
performed in triplicate, with a minimum of three independent experiments. 
 
Animals 
Female athymic NCr-nu mice were purchased from the NCI-Frederick Cancer Research 
Faculty (Frederick, Maryland). The mice were housed in a specific pathogen-free facility and 
used at seven to eight weeks of age. The care and use of laboratory animals were in 
accordance with the principles and standards set forth in the Principles for Use of Animals 
(NIH Guide for Grants and Contracts), the Guide for the Care and Use of laboratory animals 
and the provisions of the Animal Welfare Acts. The ACUF Protocol (#11-07-12731) was 
approved on November 21. 2007. 
 
Reagents 
Paclitaxel (Taxol, Bristol Myers Squibb) was obtained from the MD Anderson Cancer 
Center central pharmacy. It was stored at room temperature and diluted with phosphate 
buffered saline (PBS). Two doses of paclitaxel were defined: low dose (LD) 15 mg/kg twice 
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a week, and high dose (HD) 24 mg/kg twice a week.  Bevacizumab (Avastin, Genentech) 
was obtained from the MD Anderson Cancer Center central pharmacy and was stored at 4°C. 
Two doses of bevacizumab were defined: low dose (LD) 5 mg/kg twice a week, and high 
dose (HD) 10 mg/kg twice a week. Both experiments were conducted separately. 
In the LD experiment mice were randomized into four groups (n=10/group) and the 
following treatments were initiated: (a) vehicle control (PBS i.p. injection twice a week), (b) 
paclitaxel (15 mg/kg i.p. injection twice a week), (c) bevacizumab (5 mg/kg i.p. injection 
twice a week, and (d) the combination of paclitaxel and bevacizumab (same doses, i.p. 
injection twice a week). 
In the HD experiment mice were randomized into four groups (n=10/group) and the 
following treatments were initiated: (a) vehicle control (PBS i.p. injection twice a week), (b) 
paclitaxel (24 mg/kg i.p. injection twice a week), (c) bevacizumab (10 mg/kg i.p. injection 
twice a week, and (d) the combination of paclitaxel and bevacizumab (same doses, i.p. 
injection twice a week). Following 3 weeks of therapy, mice were sacrificed. Body weights 
were recorded, and tumors were weighed and collected. 
The description of the treatment is depicted in Figure 4. 
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Figure 4 - Description of the Experimental Treatment 
Details of the treatment
ACUF Protocol # 11-07-12731
180 Mice
45 Mice 45 Mice 45 Mice 45 Mice
mfp* mfp mfp mfp
Tumor /          2x106 GILM2 Cells/0.1 ml    2x106 GILM2 Cells/0.1 ml    2x106Cells GILM2/0.1 ml 2x106 GILM2 Cells/ 0.1 ml
Cell 
Injection: 
Treatment Regimen: PBS Bevacizumab Paclitaxel             Bevacizumab/Paclitaxel           
0.1 ml** LD 5 mg/Kg/twice week LD 15 mg/kg/twice week      Same combination
HD 10 mg/Kg/twice week        HD 24 mg/kg/twice week
Mice examined daily for size of tumor and signs of lethargy,
loss of grooming habits, loss of appetite, and loss of activity,
anorexia, >10% weight loss, ascites and dyspnea. Mice will be
sacrificed when mice demonstrate signs of lethargy.
Mice sacrificed at various times as indicated in following pages. 
*mfp:mammary fat pad
**Total Volume of IP drug injected 0.1 ml for all drugs.
LD: low dose; HD: high dose
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Tumor Growth 
For all in vivo experiments, tumor cells in exponential growth phase were harvested by brief 
exposure to 0.25% trypsin in 0.02% EDTA, then washed and resuspended in Ca2+ and Mg2+ 
free PBS, to give a dose of 2.5 x106 cells in 100µl. This dose of cells was injected into the 
mammary fat pat (mfp) of mice. Local tumor growth was measured at two weekly intervals, 
using calipers, recording two perpendicular diameters to calculate the mean tumor diameter. 
Tumors were established by implantation of human breast cancer cell line GILM2 
(dose 2x106 cells/0.1 ml) into mammary fat pad (mfp) in 5 – 6 weeks old female mice. Mice 
were monitored twice a week for tumor growth, and experiments were performed on week 4-
5 after injection on mice bearing tumors ranging in size between 0.5 cm3 and 1 cm3. 
Mice were kept under specific pathogen-free condition. Sterilized food and tap water 
were given ad libitum. Drug efficacy was assessed in terms of tumor volume and body 
weight, and was recorded three times a week. Tumor volume were calculated as V = a2 x b x 
π/6, where a and b equal the short and the long diameter of the tumor, respectively. Once 
tumors became median size of 500 mm3, approximately at day 45 of the experiment, mice 
were treated with i.p. injection of paclitaxel and bevacizumab twice a week. Measured tumor 
of 1.5 cm mean diameter were either surgically removed and the incision closed with wound 
clips, or the mouse was euthanized. All mice were necropsied, and tumors removed for 
culture and/or histopathological analysis after three weeks of treatment. All in vivo 
experiments were conducted in accordance with the guidelines of the MD Anderson Cancer 
Center Animal Care and Committee. 
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Interstitial Fluid Pressure Measurement. 
Tumor IFP was measured using the ultraminiature tipped catheter described by Dr. Ozerdem. 
[85] Following general anesthesia with isoflurane (1.5%-2.5% isoflurane delivered at 1-2 
L/min) ultraminiature transducer-tipped catheter in which the sensor is side-mounted at the 
tip: SPC-320 transducer (2 French in size, 0.66 mm in diameter) and the ultraminiature 
pressure transducer were introduced into the tumor protected with 18-gauge needle to the 
core of the tumor. The Mikro-Tip (PSC-320 Millar) was connected to transducer Millar. The 
transducer was connected to a PowerLab 8/30 amplifier and the data was imported into 
software to a Macintosh computer. Records of tumor IFP were done in mm Hg. The needle 
was removed slowly while the sensor was introduced into the center of the tumor. The 
location of the center of the tumor is estimated by dividing the caliper-measured diameter of 
tumor in half. This procedure was performed at baseline and then twice per week. Each 
measurement lasted approximately 3 to 5 minutes. The tumor measurement equipment is 
depicted in Figure 5. 
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Figure 5 - Equipment to assess the IFP with ultraminiature pressure transducer. 
A. The ultraminiature transducer (arrow) is introduced percutaneously into a surface of the 
tumor in a protective metal guide (18-gauge needle) (arrowhead). 
B. The needle is withdrawn slowly, while the sensor is introduced into the center of the 
tumor. The location of the center of the tumor is estimated by dividing the caliper-measured 
diameter of tumor in half. The transducer can be marked for millimeter gradation using 
standard fine point pens. 
C. Handling of the needle guide and transducer is very easy during microsurgical procedures 
on mice. Scale bar = 600 µm. Pictures A, B, and C were obtained from Ozerdem and 
Hargens. [85] 
D. Millar catheter introduced into the 18-gauge needle. F. Mac Laptop, connected to 
PowerLab 8/30 amplifier and the data was imported into software to a Macintosh computer. 
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Figure 5: Interstitial fluid pressure measurement with ultraminiature pressure transducer. 
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Immunohistochemistry Analysis 
Tumor tissue was fixed in 10% buffered formalin for paraffin embedding, or frozen in OCT 
compound (Miles Laboratories, Elkhart, Indiana) in liquid nitrogen. For assessment of blood 
vessel quantification, 5µm frozen tissue sections were cut, fixed in acetone and stained with 
antibodies to CD31/PECAM-1 (PharMingen, Sand Diego, California) with fluorescent Alexa 
647 antirat secondary antibody (Invitrogen). This experiment has been described elsewhere. 
[86] Non-specific IgG was used for control reactions. Areas of sections with the highest 
numbers of stained capillaries and small venules were identified by scanning the sections at 
low power magnification (40X). Images of 10 fields at higher magnification (100X) from 
these selected areas were captured using a digital camera and stored for analysis.  
ImageJ software (National Institute of Health) was used to assess vessel area, vessel 
diameter, and length. Vessel area was calculated from number of pixels stained with CD31 
per high-power field. Vessels diameter and length were calculated from measuring pixels of 
each vessel at its largest diameter or length and converting pixels to micrometers. Sections 
were counterstained with hematoxylin. The CD31 and pericyte staining, area was quantified 
(40X objective, 20 fields from each slide) by using ImageJ software (National Institute of 
Health). 
Sections of paraffin-embedded tumor that had been formalin-fixed were used to identify 
cleaved-caspase 3. Immunohistochemistry using the rabbit anti-cleaved caspase 3 antibody 
was performed on deparaffinized tissue sections using a routine avidin-biotin-
immunoperoxidase technique [Vectasin Elite avidin-biotin-immunoperoxidase kit reagents 
(Vector Labs, Burlingame, CA)]. Before incubation with the primary antibody (1:200 
  
37 
 
dilution as supplied by the manufacturer), tissue sections were subjected to heat-induced 
epitope retrieval by incubation in a Ph 8.0 0.01 M EDTA solution for 10 min in a vegetable 
steamer, followed by 20-min cool-down and treatment with 3% hydrogen peroxide before 
antibody application. Microscopy: fluorescence images were prepared using a Zeiss 
Axioplan 2 microscope equipped with phase-contrast optics and with rhodamine and UV 
channel filters. Images were recorded using either a Dage 300 monochrome CCD camera or 
a Zeiss Axiocam CCD camera, and composite figures were prepared using Adobe Photoshop. 
 
Immunofluorescence double staining for CD31 and Desmin 
Sections were fixed in cold acetone for 10 min, blocked with protein blocker for 20 min at 
room temperature, incubated with CD31 antibody (1:400; PD PharMiagen) overnight at 4°C 
followed by incubation with Alexa Fluor 594-conjugated with anti-rat antibody (1:1,000; 
Invitrogen) for 1 hour at room temperature. After washing with PBS, samples were incubated 
with desmin antibody (1:400; DakoCytomation) for 1 hour and followed by incubation with 
Alexa Fluro 488-congugated anti-rabbit antibody (1:1,200; Invitrogen) for 1 hour at room 
temperature. Samples were counterstained with Hoechst for 5 min and mounted. 
 
Hypoxia Measurement 
Pimonidazole hydrochloride (HypoxyProbeTM, 100 mg/kg/0.2 ml PBS) was administered IP 
to tumor-bearing mice and this agent is metabolized and bound to hypoxic cells within the 
tumor. [87] Three hours after injection, tumors were excised and frozen in liquid nitrogen. 
Frozen sections (10µm thick) from the central regions of tumors were fixed for 15 min in 4% 
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FBS, 5% nonfat milk, and 0.1% Triton X-100 in PBS. Slides were incubated for 1 hour at 
room temperature with an FITC-conjugated monoclonal antibody against pimonidazole 
(1:20) (Millipore) and counterstained with 50 nM propidium iodine (PI). FITC and PI 
fluorescent signals for entire tumor sections (one section per tumor) were acquired on a 
Nikon Eclipse E800 microscope equipped with motorized scanning stage, a 12-bit QImaging 
camera (QImaging, Burnaby, Canada) 
 
Lectin Perfusion and Tumor Vascular Staining. 
Mice were anesthetized and injected intravenously (tail vein injection) with 100 µl of 
fluorescein Lycopersicon esculentum lectin (Vector Laboratories). Ten minutes later, we 
perfused mice through the ascending aorta with 4% paraformaldehyde for 2 minutes. Tumors 
were extracted, placed in 4% paraformaldehyde for another 2 hours followed by immersion 
in 30% sucrose/PBS overnight. Tumor samples were then embedded in OCT, and cryostat 
sectioned for visualization using confocal fluorescence microscopy. 
 
Intratumoral Drug Distribution of Labeled-Paclitaxel 
In this aim, we aimed to investigate the influence of bevacizumab on the antitumor activity of 
paclitaxel and the intratumoral distribution in GILM2 model. This aim was conducted under 
the guidance of Dr. William G. Bornmann, Professor of Experimental Therapeutics. Thirty 
mg of paclitaxel were conjugated to Dansyl dye. Reconstitution was done in DMSO 
following by i.p. injection of 24 mg/kg of labeled-paclitaxel. Dansyl chloride or 5-
(dimethylamino) naphthalene-1-sulfonyl chloride is a reagent that reacts with primary amino 
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groups in both aliphatic and aromatic amines to produce stable blue- or blue-green-
fluorescent sulfonamide adducts. The absorption value was always taken at the maximum 
that appears between 310 nm and 350 nm. The conjugations of dansyl chloride with 
paclitaxel in the tumor possess a dark blue color. 
 
Determination of Transcapillary Transport of Paclitaxel into the Tumor Tissue Using Liquid 
Chromatography/Mass Spectrometry (LC/MS) 
LC/MS is a simple, rapid and sensitive analytical method for quantifying paclitaxel in tissue 
homogenates.[88]  This aim was conducted under the guidance of Dr. Timothy L. Madden, 
Director of the Pharmacology and Analytical Facility. This method combines a one-step 
liquid-liquid sample extraction with ESI ± MS/MS detection to achieve the selective and 
specific quantization of paclitaxel. The assay has been fully validated by previous preclinical 
studies at MD Anderson Cancer Center. [89, 90] 
 
Statistical Analysis 
All experiments were repeated at least two times on different occasions. The results are 
presented as the mean ± 95% confidence intervals for all values. All data were analyzed 
using GraphPad Prism 4 (GraphPad Software, Inc) and the Mann-Whitney nonparametric t 
test. A p value of <0.05 was considered statistically significant. 
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Results 
 
The experiment aims and the diagram of treatment plan is depicted in Figure 6. 
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Figure 6 
Flow Sheet of the Treatment
In vivo studies:
IFP*: During the first week of experiment  a total of 3 measurements, and during the 2nd and 3rd weeks one 
measurement each week.
Perfusion study: During the first week of the experiment a total of 2 assays, and during the 2nd and 3rd weeks 
one assay each week.
Hypoxia study: During the first week of the experiment a total of 2 assays, and during the 2nd and 3rd weeks 
once each week.
Tumor Volume measurement: two times a week.
Diagram of Treatment Plan:
IFP*:Interstitial Fluid Pressure; IHC: Immunohistochemistry
Days/
Drug
1 2 3 4 5 6 7 8 9 10 11 1
2
13 14 15 16 17 18 19 20 21 22
PBS x x x x x x
Bev x x x x x x
Pac x x x x x x
Bev/
Pac
x x xx x x xx x x xx
•IFP:                   ↑ ↑ ↑ ↑ ↑
• Perfusion ↑(4)        ↑(3 per arm) ↑(3 per arm) ↑(3 per arm)
• HypoxyProbe ↑(4) ↑(3 per arm) ↑(3 per arm) ↑(3 per arm)
• Paclitaxel         ↑(4) ↑(3 per 2 arms) ↑(3 per 2 arms) ↑(3 per 2 arms)
Assay
• IHC ↑(4) ↑(3 per arm) ↑(3 per arm) ↑(3 per arm)
Sacrificed mice: 16 42 42 42
Remaining alive:164 122 80 38
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In vitro treatment of culture cells using paclitaxel and bevacizumab 
The GILM2 breast cancer human cell line was used for this experiment. The cells were 
determined to be free of mycoplasma and 17 different murine viral pathogen before use.  
Clonogenic Assay  
The combination of paclitaxel plus bevacizumab and paclitaxel as single agent results in no 
visible colonies. (Figure 7 a) The bevacizumab and control dishes have colonies in the same 
proportion. The interpretation of this experiment is that the GILM2 breast cancer cells are 
sensitive to paclitaxel, and insensitive to bevacizumab. One conclusion of this experiment is 
the absence of bevacizumab sensitivity response might be mediated by the lack of VEGF 
receptors in the tumor cell.  
MTT Assay 
We performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide (MTT) to 
correlate with the clonogenic assay performed. Several serial dilutions of bevacizumab and 
paclitaxel plus bevacizumab were performed and we found similar results to those of the 
clonogenic assay. The plots in Figure 7 b, demonstrated that GILM2 is insensitive to 
increasing doses of bevacizumab as single agent as well in combination with paclitaxel. 
GILM2 cells are sensitive to paclitaxel. Increasing paclitaxel doses produced a dose response 
curve. 
  
43 
 
Figure 7 
a. Clonogenic assay performed in 4 Petri dishes, with GILM2 1 x 102 breast cancer  
cells. The control group was treated with PBS only, the paclitaxel flask was treated with 5 
nM of paclitaxel, the bevacizumab flask was treated with 10 μg/ml, and the 
paclitaxel/bevacizumab flask was treated with 5 nM of paclitaxel and 10 μg/ml. The control 
and bevacizumab dishes showed a persistence of colonies. The paclitaxel and combination of 
paclitaxel and bevacizumab showed a complete absence of visible colonies. 
 
b. Proliferative assay 
Upper graphic: Serial dilution of bevacizumab and paclitaxel in combination with 
bevacizumab were placed in 96-well microplate. 
Lower graphic: the breast cancer tumor cell line GILM2 in exponential growth was exposed 
to increasing nanomolar concentration of paclitaxel. Paclitaxel showed a dose response curve 
with an estimation of IC50 value of 5.2. 
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Figure 7a: In vitro activity of paclitaxel and bevacizumab. Clonogenic Assay 
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Figure 7b: GILM2 in vitro analysis  
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Tumor growth inhibition by the combination of paclitaxel and bevacizumab 
To determine whether the treatment with paclitaxel and bevacizumab is effective to eradicate 
tumors in vivo, we conducted two independent experiments using two different 
chemotherapy schedules: low dose (LD) and high dose (HD). We first tested the effects of 
the low dose of paclitaxel (15 mg/kg) plus bevacizumab (5 mg/kg) on GILM2 tumor 
xenografts. Overall, the therapies were well tolerated by the mice. Compared with the control 
mice, a 3% to 9% weight decrease was noted in the treatment groups with the greatest 
decrease observed in the combination group (data not shown). No mice in any of the 
treatment groups appeared moribund or ill before sacrifice and no hemorrhagic or infection 
complications were observed. Not all mice developed primary mfp tumors (85% 
tumorigenicity). 
LD Experiment: Mice treated with the combination of paclitaxel and bevacizumab inhibited 
tumor growth by 41% reduction mean of tumor volume of the mfp breast tumors compared 
with the tumors in the control group. (Figure 8 a and b) However this reduction was not 
statistically significant (t test p = 0.1720). The combination of paclitaxel and bevacizumab 
substantially inhibited tumor growth more than either therapy alone.  Paclitaxel single agent 
produced a reduction of 32.77% compared with control. Finally, treatment with bevacizumab 
produced minimal effect on the tumor control with reduction on 8% the mean of tumor 
volume. Tumor weight mirrored the changes observed for tumor volume (data no shown). 
HD Experiment: Mice treated with paclitaxel and paclitaxel plus bevacizumab inhibited 
tumor growth by 56.1% in the mean volume of the mfp breast tumors compared with the 
tumors in the control group. (Figure 8 c and d) The difference of tumor volume between the 
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combination of paclitaxel plus bevacizumab and control group was statistically significant. (t 
test p = 0.0183) The treatment with paclitaxel as single agent reduced the tumor volume by 
50% (t test p = 0.0270). Bevacizumab reduced the tumor volume by 31.9%; however, 
compared with control group this is not statistically significant. (t test p = 0.1572) 
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Figure 8 a and b: In vivo Activity of Low Dose Treatment 
Figure 8 c and d: In vivo Activity of High Dose Treatment. 
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Figure 8 - In vivo activity of paclitaxel and bevacizumab in GILM2 breast cancer tumor 
xenografts 
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Treatment with the combination of paclitaxel and bevacizumab decreases the tumor IFP 
Basal Tumor IFP 
Tumor IFP (mmHg) was evaluated in a wide range of experimental models at the baseline. 
We found a positive correlation (Pearson r 0.4632; p = 0.0044) with tumor IFP and tumor 
volume (mm3)  (Figure 9 a). 
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Figure 9 
 
Correlation Analysis 
Pearson r   0.4632 
95% confidence interval  0.1587 to 0.6872 
P value (two-tailed)  0.0044 
R squared   0.2145 
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Effect of Treatment on Tumor IFP 
GILM2 breast cancer cells were implanted into mfp. We tested whether treatment with LD or 
HD decreased the tumor IFP. In the LD experiment there was no statistically significant 
difference between arms comparing day 1 to day 21. (Figure 9b) Tumor IFP fluctuated 
during treatment arms especially with paclitaxel; however, the IFP level returned to similar 
baseline point. In the HD group, the combination of paclitaxel and bevacizumab resulted in 
statistically significant reduction of IFP (p = 0.0068) compared with the other the arms. 
(Figure 9 c) 
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Figure 9b: Tumor IFP in the Low Dose Group 
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Figure 9c: Tumor IFP in the High Dose Group 
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Combination of paclitaxel and bevacizumab significantly increase tumor apoptosis. 
It is now clear that caspase activation (cleavage of procaspase to active caspase) is a hallmark 
of almost all apoptotic systems. We tested whether induction of tumor cell death might also 
contribute to the antitumor activity of bevacizumab in combination with paclitaxel.  
These results (Fig 10) suggested that induction of apoptosis by the combination of paclitaxel 
and bevacizumab compared with either agent alone or vehicle, might contribute, at least in 
part, to the inhibition of tumor growth.  
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Figure 10 - Detection of cleaved caspase 3 in apoptotic cells in paraffin sections. 
Localization of cleaved caspase 3 in deparaffinized sections of formalin –fixed tissues.  
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Figure 10: 
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Combination of paclitaxel and bevacizumab increases the diameter of tumor vessels and 
decrease the pericyte coverage. 
To assess whether neoplastic cell loss would decompress blood vessels, we measured vessel 
diameter in GILM2 mfp tumors. Paclitaxel increased the diameter of blood vessels at day 7, 
14 and 21; however, there were no changes in vessel density. The vascular diameter of 
treated tumor was increased significantly when bevacizumab was added to paclitaxel, 
doubling the vascular diameter and indicating that the vascular surface area increased 
approximately by 2-fold. Next, we examined pericyte coverage using dual 
immunofluorescence staining for CD31 and desmin. In normal tissues we found that small 
vessels (venules and capillaries) were covered extensively by irregularly shaped pericytes 
that were associated tightly with the endothelial cells. We found that pericytes were localized 
in the growing tips or angiogenic “sprouts” of new blood vessels. (Figure 1 b) However, 
tumor vessels were morphologically abnormal and tortuous in shape with irregular pericyte 
coverage. Although most tumor vessels had pericyte coverage, the pericytes were attached 
loosely and had extensions projecting both toward the endothelial cells and the tumor stroma. 
After one week of treatment with paclitaxel with and without bevacizumab, there was an 
increase in pericytes covering the blood vessels and also extending into the tumor stroma.  
(Figure 11 a) The pericyte recruitment might be secondary to tissue stress after treatment 
with chemotherapy. Subsequently, after 2 weeks of treatment, the blood vessels become 
enlarged, with patchy endothelial coverage and small amounts of pericytes. (Figure 11 b) At 
the end of third week of treatment, the group treated with the combination of paclitaxel and 
bevacizumab were characterized by absence of lumen of blood vessels and practically 
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complete disappearance of pericytes. This effect is more pronounced in the group that 
received the combination of paclitaxel and bevacizumab than the group that received 
paclitaxel single agent. (Figure 11c) The stained area in 20 fields was quantified by using 
ImageJ software. Mean ± SEM (5 mice each) are shown. ∗, P < 0.01 (Student’s t test). 
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Figure 11 - performed to visualize endothelial cells and pericytes. Images were taken at 
original magnification (X400).   Pericyte coverage of small vessels in breast carcinoma. The 
percentages of vessels with at least 50% coverage of associated desmin-positive cells were 
counted. 
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Figure 11a: Immunofluorescence Analysis of Paclitaxel and Paclitaxel plus 
Bevacizumab over Three Weeks Treatment 
Paclitaxel Single Agent  Paclitaxel plus Bevacizumab 
a. 
  
b. 
  
c. 
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Figure 11 b: Quantification of endothelial cells, pericytes and apoptosis during the treatment 
with paclitaxel and bevacizumab. 
 
 
Figure 11 c: Quantification of Blood vessel characteristics. 
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Tumor distribution of labeled-paclitaxel improved with the addition of bevacizumab. 
To assess whether pretreatment with bevacizumab is associated with tumor concentration of 
paclitaxel, we studied paclitaxel distribution in GILM2 tumor xenografts.  The distribution of 
labeled-paclitaxel within GILM2 xenografts was observed by examining tumors excised at a 
range of time points after i.p. administration of the drug. Tumor cryosections were imaged 
and stained immunohistochemically for combinations of paclitaxel, and endothelial cell 
marker CD31 (red). 
 
Distribution of paclitaxel through tumors. Mice bearing GILM2 xenografts were given single 
i.p. doses of 24 mg/kg labeled-paclitaxel. A group of mice (4 per group) received 
bevacizumab 10 mg/kg and other group received PBS (control). Representative high 
resolution composite images for whole tumor sections obtained 2 to 2.5 mm from the tumor 
edge were generated with a magnified portion of an untreated control tumor shown in Figure 
12. Similar images of treated tumor show paclitaxel-labeled (blue) proximal to vasculature 
(CD31 in red) 
As shown in Figure 12, paclitaxel distribution into the tumor tissue was, in general, higher in 
the bevacizumab treated group, with the difference in mean paclitaxel tumor concentration 
between the groups reaching statistical significance at 24hs and 48 hs. 
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Figure 12 - Distribution of labeled-paclitaxel into the tumor 
a. Labeled-paclitaxel and vessels analysis on cryosections of GILM2 xenografts tumors in 
paclitaxel and paclitaxel plus bevacizumab treated. Representative images show differences 
in vessel morphology with CD31 staining. Intratumor distribution of labeled-paclitaxel (blue) 
and nuclear staining with Cytoxgreen (green). 
b. Graphical representation of image analysis of intratumor paclitaxel distribution. Bars 
represent means values ±SEM (n = 4 per group). * P < .05, versus control. 
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a. Effect of Bevacizumab in Tissue Paclitaxel Distribution 
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b. Quantification of Labeled-Paclitaxel 
0
10
20
30
40
50
60
70
80
90
Paclitaxel 24 hs Paclitaxel/Bevacizumab 24 
hs
Paclitaxel 48 hs Paclitaxel/Bevacizumab 48 
hs
Paclitaxel Tumor Distribution
Pixel Intensity
Pixel Intensity
Pixel Intensity
*
*
 
 
  
68 
 
LC/MS Analysis 
In this aim, we documented the amount of paclitaxel accumulation in the tumor and this was 
directly analyzed by LC/MS. We used ANOVA test to determine whether or not there is a 
statistically significance difference among the means of two group. 
Low Dose Experiment: 
Eighteen mice were randomized in two arms: paclitaxel 15 mg/kg, and paclitaxel (same dose) 
plus bevacizumab (5 mg/kg). At the end of each week, 3 mice were sacrificed and tumor 
removed. The comparison between the single agent paclitaxel versus the combination 
paclitaxel and bevacizumab was statistically significant (1 way ANOVA; p = 0.0457) 
High Dose Experiment: 
Eighteen mice were randomized in two arms: paclitaxel 24 mg/kg, and paclitaxel (same dose) 
plus bevacizumab (10 mg/kg). At the end of each week, 3 mice were sacrificed and tumor 
removed. The comparison between the single agent paclitaxel versus the combination 
paclitaxel and bevacizumab was not statistically significant (1 way ANOVA; p = 0.2224) 
The comparison between the LD and HD was statistically significant (1 way ANOVA; p = 
0.0257) 
Our conclusion of this experiment was that intratumor paclitaxel accumulation 
increases when low dose of paclitaxel and bevacizumab are given together compared with 
paclitaxel single agent. At these low doses synergistic effect was demonstrated using this 
drug combination. This synergistic effect was not observed when combinations of high doses 
of same drugs were used. 
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Figure 13 - Chromatography/Mass Spectrometry (LC/MS) 
Eighteen samples were collected for LD and HD treatment. 
a. Tissue paclitaxel accumulation in the low dose treatment.  
b. Tissue paclitaxel accumulation in the low dose treatment.  
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Figure 13: Liquid Chromatography/Mass Spectrometry (LC/MS) 
a. Tissue paclitaxel accumulation in the low dose treatment 
 
b. Tissue paclitaxel accumulation in the high dose treatment 
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Discussion 
Traditionally, cancer treatment has focused on targeting the tumor cells directly. It has, 
however, become clear that tumor cells interact with and are dependent on surrounding 
normal cell types in the tumor. So, targeting of non-malignant cell types, in parallel to the 
tumor cells, might represent the future of cancer treatment. Combination therapy with an 
antiangiogenic agent plus chemotherapy acts at multiple targets within the tumor, depriving it 
of nutrients and oxygen (i.e. antivascular and antiangiogenic effects) and killing highly 
proliferative tumor cells (i.e. cytotoxic effects) [91]. 
To summarize, the studies presented in this thesis have investigated the effects of the 
combination of paclitaxel and bevacizumab on tumor growth, tumor IFP, transvascular 
transport, and tissue paclitaxel distribution. It has conclusively demonstrated that the addition 
of bevacizumab to paclitaxel increases the drug uptake, thus decreasing the IFP and 
increasing significantly the tissue apoptosis.  
It is believed that in the presence of a normal vasculature paclitaxel crosses 
membranes by diffusion; however, in tumors, convective transport is influenced by changes 
in IFP. In this study, the tumor IFP decreased significantly when paclitaxel is combined with 
bevacizumab. In contrast to some early animal model studies demonstrating that anti-VEGF 
agent decreases the tumor IFP, [75] [76] our observation together with other authors [92] 
demonstrated that single agent of anti-VEGF (bevacizumab) does not affect the tumor IFP  
Our work as well the work of others [93] has shown that tumor IFP measurements can 
predict tumor response in patients. The mechanisms responsible for the changes in tumor IFP 
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during treatment are poorly understood. This study provides insights into the interrelationship 
among neoplastic cells, tumor vasculature, tumor IFP, and drug uptake by the tumor. 
Chemosensitization is the ability to augment the effects of standard chemotherapy. 
One of the possible mechanisms for chemosensitization is improving intratumoral 
chemotherapy concentrations by increasing total or regional delivery of chemotherapy to the 
tumor. This mechanism potentially leads to a decreased tumor IFP. However, results from 
two different groups [94, 95] demonstrated that the induction of apoptosis by the action of 
taxanes -docetaxel and paclitaxel, causing and decompressing blood vessels can also reduce 
tumor IFP. As antiangiogenic agents are generally cytostatic rather than cytoreductive, 
combinations involving conventional cytotoxic chemotherapies may be useful for 
maximizing therapeutic activity. The net outcome of a combination therapy is determined by 
the balance between antiangiogenic potential and cytotoxicity. In this preclinical work, we 
found that low dose combination of paclitaxel plus bevacizumab produces a synergistic effect 
with increased intra-tumor paclitaxel concentration when bevacizumab is added. In contrast, 
the high dose of treatment produced no statistical significant increment of paclitaxel 
accumulation into the tumor. But at the same time, effective tumor control was seen only 
with the high doses of treatment. The same effect has been seen in the clinic where improved 
clinical responses were observed when conventional chemotherapy is combined with low-
dose of bevacizumab compared with high dose bevacizumab. [96]  
There are two lines of investigation that would benefit from further studies. First, 
there is much to do to fully understand the mechanism behind the increased IFP of solid 
tumors and to find ways to lower tumor IFP. Most importantly, the concept of lowering 
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tumor IFP and improving tumor efficacy needs to be validated in the clinic. So far, there is 
only one study demonstrating that the IPF was an independent prognostic parameter to 
disease-free survival in cervical carcinoma patients treated with radiation therapy. A 
decreased IFP at early phase of the beginning of the neoadjuvant treatment can be used as 
early surrogate of tumor response in breast cancer patients. This effect would improve the 
current tumor assessment and impact in the management of breast cancer patients treated 
with primary systemic therapy.  
Second, we need to repeat the experiment using the same preclinical protocol 
assessing tumor response by dynamic contrast enhanced magnetic resonance imaging (DCE-
MRI). In our prior experience with DCE-MRI we found multiple technical difficulties related 
to the site of implantation of mfp and the experiment found no differences in blood flow and 
permeability, besides good tumor control in the combination arm with paclitaxel and 
bevacizumab. Tumor blood flow is highly heterogeneous. It is not the total blood flow, but 
the distribution of blood flow that determines the distribution of a drug or oxygen in tumors. 
Therefore, the global (total) blood flow, as estimated by the currently available resolution of 
DCE-MRI or CTs, does not inform us about the degree of spatial heterogeneity in vascular 
normalization of distribution. An alternative approach will be investigated in the future using 
an ultrasound Doppler to characterize the blood vessels morphology. Thus, there is real 
necessity to improve our imaging techniques with higher resolution of the temporal changes 
in blood flow and other physiological parameters. This is a real unmet need to definitively 
establish the effects of antiangiogenic treatment on vascular function. 
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Neoadjuvant chemotherapy for the treatment of breast cancer has been used for 
almost four decades and it is considered the initial component of the multidisciplinary 
approach for the treatment of patients with locally advanced and large operable breast cancer. 
This approach has been proven save and as effective as adjuvant therapy. Although of the 
more convincing arguments for the neoadjuvant treatment its value as an in vivo test for drug 
sensitivity, the major advantage of this treatment modality is the increase of the breast-
conservative approach. Several studies in breast cancer patients treated with neoadjuvant 
treatment showed that drug sensitivity correlates with survival. Several aspects of the 
neoadjuvant therapy remain to be confirmed and validated in prospective trials. After many 
years of investigations, many questions remain regarding the best chemotherapy, sequence of 
different regimens, and length of treatment. Recently, neoadjuvant chemotherapy provides an 
ideal scenario for determining prognostic and predictive factors of response to specific 
regimens. The pathologic complete response (pCR) is the major surrogate endpoint; 
however, pCR occurs several months after the initiation of neoadjuvant chemotherapy. We 
believe that early changes in the tumor IFP might be correlated with tumor response. A report 
by Milosevic and collaborators [59] has shown that the tumor IFP can predict survival in 
patients with cervix cancer treated by radiation therapy, independently of other clinical 
factors, suggesting that it is a potential useful parameter of response. Currently, I have 
developed an exploratory biomarker study to analyze changes in tumor IFP during 
neoadjuvant treatment in breast and malignant melanoma patients. I am planning to use the 
same IFP instrumentation for intratumor hypertension assessment that was utilized in this 
preclinical experiment. 
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The administration of single agent anti-VEGF such as bevacizumab, sorafenib and 
sunitinib has demonstrated a modest tumor activity in MBC with responses rate of 6%, 2%, 
and 11%, respectively. Results from phase III clinical trials demonstrated that bevacizumab 
in combination with chemotherapy had clinical benefit in previously untreated breast, lung 
and colorectal cancer when compared with standard chemotherapy alone. [97-99] Although 
three large randomized clinical trials in advanced breast cancer patients using paclitaxel plus 
bevacizumab have demonstrated positive results increasing consistently the progression free 
survival, the FDA has recently questioned the efficacy of bevacizumab. Several preclinical 
studies using animal models have demonstrated that the combination of anti-angiogenic 
agent with cytotoxic drug is superior compared with single agent treatment. After two years 
working with animal models using different combination of the aforementioned drugs, this 
study suggests that bevacizumab might modify temporarily the transvascular transport of the 
cytotoxic agent, thus acting as chemosensitizer more than cytostasis. 
 
 
 
  
76 
 
BIBLIOGRAPHY 
1 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J 
 Clin 2007;57:43-66. 
2 Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin;60:277-300. 
3 Garcia M, Jemal A, Ward E: Global cancer facts and figures 2007. 
4 Ravdin P, Cronin KA, Howlader N, Berg CD, Chlebowski R, Feuer EJ, Edwards BK, Berry 
 DA: The decrease in breast-cancer incidence in 2003 in the united states. N Engl J Med 
 2007;356:1670-1674. 
5 Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer 
 survival improving? Cancer 2004;100:44-52. 
6 Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-
 Giralt E, Keiling R, Namer M, Closon MT, et al.: Phase ii trial of weekly intravenous 
 vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-
 1252. 
7 Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz  BB, 
 Long CA: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating 
 factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-
 1400. 
8 Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, 
 Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J: Gemcitabine plus 
 paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior 
 anthracycline treatment. J Clin Oncol 2008;26:3950-3957. 
  
77 
 
9 Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger 
 HU, Brown CS, Griffin T: Multicenter phase ii study of capecitabine in paclitaxel-
 refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493. 
10 O'Shaughnessy JA: Potential of capecitabine as first-line therapy for metastatic breast 
 cancer: Dosing recommendations in patients with diminished renal function. Ann Oncol 
 2002;13:983. 
11 Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, 
 O'Shaughnessy J: Phase iii trial of nanoparticle albumin-bound paclitaxel compared with 
 polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 
 2005;23:7794-7803. 
12 Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, 
 Steinberg SM, Mannan N, Fojo T, Swain SM: Phase ii clinical trial of ixabepilone (bms-
 247550), an epothilone b analog, in metastatic and locally advanced breast cancer. J Clin 
 Oncol 2005;23:2726-2734. 
13 Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell 
 CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, 
 Lebwohl D, Martin M: Phase ii clinical trial of ixabepilone (bms-247550), an epothilone b 
 analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 
 2007;25:3399-3406. 
14 Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney 
 B, Peck R, Hortobagyi GN: Efficacy and safety of ixabepilone (bms-247550) in a phase ii 
 study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and 
 capecitabine. J Clin Oncol 2007;25:3407-3414. 
  
78 
 
15 Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, 
 Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Cure H: Phase ii clinical trial of ixabepilone 
 (bms-247550), an epothilone b analog, as first-line therapy in patients with metastatic breast 
 cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-
 3420. 
16 Arriagada R, Spielmann M, Koscielny S, Le Chevalier T, Delozier T, Ducourtieux M, Tursz 
 T, Hill C: Patterns of failure in a randomized trial of adjuvant chemotherapy in 
 postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol 
 2002;13:1378-1386. 
17 American Cancer Society: Cancer facts and figures. Atlanta, American Cancer Society,  
 2008. 
18 Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627. 
19 Tannock IF: Tumor physiology and drug resistance. Cancer Metastasis Rev 2001;20:123-
 132. 
20 Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 
 2005;205:275-292. 
21 Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1889:571-
 573. 
22 Talmadge JE, Fidler IJ: Aacr centennial series: The biology of cancer metastasis: Historical 
 perspective. Cancer Res;70:5649-5669. 
23 Dvorak HF: Tumors: Wounds that do not heal. Similarities between tumor stroma 
 generation and wound healing. N Engl J Med 1986;315:1650-1659. 
  
79 
 
24 Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 
 2001;411:375-379. 
25 Carmeliet P, Collen D: Molecular basis of angiogenesis. Role of vegf and ve-cadherin. Ann 
 N Y Acad Sci 2000;902:249-262; discussion 262-244. 
26 Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70. 
27 Cairns R, Papandreou I, Denko N: Overcoming physiologic barriers to cancer treatment by 
 molecularly targeting the tumor microenvironment. Mol Cancer Res 2006;4:61-70. 
28 Beacham DA, Lian J, Wu G, Konkle BA, Ludlow LB, Shapiro SS: Arterial shear stress 
 stimulates surface expression of the endothelial glycoprotein ib complex. J Cell Biochem 
 1999;73:508-521. 
29 Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistance and the solid tumor 
 microenvironment. J Natl Cancer Inst 2007;99:1441-1454. 
30 Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer  2006;6:583-
 592. 
31 Vaupel P: Tumor microenvironmental physiology and its implications for radiation 
 oncology. Semin Radiat Oncol 2004;14:198-206. 
32 Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and 
 problems) for cancer therapy. Cancer Res 1998;58:1408-1416. 
33 Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW: 
 Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue 
 sarcoma. Cancer Res 1996;56:941-943. 
  
80 
 
34 Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP: Tumor hypoxia 
 has independent predictor impact only in patients with node-negative cervix cancer. J Clin 
 Oncol 2002;20:680-687. 
35 Nordsmark M, Overgaard J: Tumor hypoxia is independent of hemoglobin and prognostic 
 for loco-regional tumor control after primary radiotherapy in advanced head and neck 
 cancer. Acta Oncol 2004;43:396-403. 
36 Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-
 loop-helix-pas heterodimer regulated by cellular o2 tension. Proc Natl Acad Sci U S A 
 1995;92:5510-5514. 
37 Semenza GL: Hypoxia-inducible factor 1: Master regulator of o2 homeostasis. Curr Opin 
 Genet Dev 1998;8:588-594. 
38 Cairns RA, Papandreou I, Sutphin PD, Denko NC: Metabolic targeting of hypoxia and hif1 
 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A 
 2007;104:9445-9450. 
39 Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van 
 Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict 
 prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-
 1581. 
40 Yamagata M, Hasuda K, Stamato T, Tannock IF: The contribution of lactic acid to 
 acidification of tumours: Studies of variant cells lacking lactate dehydrogenase. Br J Cancer 
 1998;77:1726-1731. 
  
81 
 
41 Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK: Acid production in glycolysis-
 impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 
 2002;8:1284-1291. 
42 Gerweck LE, Seetharaman K: Cellular ph gradient in tumor versus normal tissue: 
 Potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-1198. 
43 Aukland K, Reed RK: Interstitial-lymphatic mechanisms in the control of extracellular 
 fluid volume. Physiol Rev 1993;73:1-78. 
44 Reed RK, Berg A, Gjerde EA, Rubin K: Control of interstitial fluid pressure: Role of beta1-
 integrins. Semin Nephrol 2001;21:222-230. 
45 Wiig H, Rubin K, Reed RK: New and active role of the interstitium in control of interstitial 
 fluid pressure: Potential therapeutic consequences. Acta Anaesthesiol Scand 2003;47:111-
 121. 
46 Starling EH: On the absorption of fluids from the connective tissue spaces. J Physiol 
 1896;19:312-326. 
47 Lund T, Onarheim H, Reed RK: Pathogenesis of edema formation in burn injuries. World J 
 Surg 1992;16:2-9. 
48 McMaster PD: The pressure and interstitial resistance prevailing in the normal and 
 edematous skin of animals and man. J Exp Med 1946;84:473-494. 
49 Hargens AR, Mubarak SJ, Owen CA, Garetto LP, Akeson WH: Interstitial fluid pressure  in 
 muscle and compartment syndromes in man. Microvasc Res 1977;14:1-10. 
50 Young JS, Lumsden CE, Stalker AL: The significance of the tissue pressure of normal 
 testicular and of neoplastic (brown-pearce carcinoma) tissue in the rabbit. J Pathol 
 Bacteriol 1950;62:313-333. 
  
82 
 
51 Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK: Interstitial hypertension in 
 superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-6694. 
52 Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, Jain RK:  Interstitial 
 hypertension in head and neck tumors in patients: Correlation with tumor size.  Cancer Res 
 1992;52:1993-1995. 
53 Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, 
 Ferrara N, Jain RK, Suit HD, Boucher Y: Anti-vascular endothelial growth factor 
 treatment augments tumor radiation response under normoxic or hypoxic conditions. 
 Cancer Res 2000;60:5565-5570. 
54 Brekken C, Bruland OS, de Lange Davies C: Interstitial fluid pressure in human 
 osteosarcoma xenografts: Significance of implantation site and the response to intratumoral 
 injection of hyaluronidase. Anticancer Res 2000;20:3503-3512. 
55 Stohrer M, Boucher Y, Stangassinger M, Jain RK: Oncotic pressure in solid tumors is 
 elevated. Cancer Res 2000;60:4251-4255. 
56 Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK: Lowering of 
 tumoral interstitial fluid pressure by prostaglandin e(1) is paralleled by an increased uptake 
 of (51)cr-edta. Int J Cancer 2000;86:636-643. 
57 Curnis F, Sacchi A, Corti A: Improving chemotherapeutic drug penetration in tumors by 
 vascular targeting and barrier alteration. J Clin Invest 2002;110:475-482. 
58 Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, Jain RK: Interstitial 
 hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor 
 oxygenation and radiation response. Cancer Res 1991;51:6695-6698. 
  
83 
 
59 Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, Hill R: Interstitial fluid 
 pressure predicts survival in patients with cervix cancer independent of clinical prognostic 
 factors and tumor oxygen measurements. Cancer Res 2001;61:6400-6405. 
60 Alvarez RH, Kantarjian HM, Cortes JE: Biology of platelet-derived growth factor and its 
 involvement in disease. Mayo Clin Proc 2006;81:1241-1257. 
61 Ostman A, Heldin CH: Involvement of platelet-derived growth factor in disease: 
 Development of specific antagonists. Adv Cancer Res 2001;80:1-38. 
62 Okuda K, Weisberg E, Gilliland DG, Griffin JD: Arg tyrosine kinase activity is inhibited by 
 sti571. Blood 2001;97:2440-2448. 
63 Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K: 
 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and 
 increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934. 
64 Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A: 
 Inhibition of pdgf receptor signaling in tumor stroma enhances antitumor effect of 
 chemotherapy. Cancer Res 2002;62:5476-5484. 
65 Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, 
 Wartmann M, Ostman A: Sti571 enhances the therapeutic index of epothilone b by a 
 tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-3787. 
66 Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A: Pdgf receptors as cancer drug 
 targets. Cancer Cell 2003;3:439-443. 
67 Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev 
 1987;6:559-593. 
  
84 
 
68 Heldin CH, Rubin K, Pietras K, Ostman A: High interstitial fluid pressure - an obstacle in 
 cancer therapy. Nat Rev Cancer 2004;4:806-813. 
69 Boucher Y, Jain RK: Microvascular pressure is the principal driving force for interstitial 
 hypertension in solid tumors: Implications for vascular collapse. Cancer Res 1992;52:5110-
 5114. 
70 Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, 2nd, Madara K, Longo DL: 
 Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: 
 Changes during treatment. Cancer Res 1993;53:2204-2207. 
71 Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK: Interstitial 
 hypertension in human breast and colorectal tumors. Cancer Res 1992;52:6371-6374. 
72 Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. I. Role of  interstitial 
 pressure and convection. Microvasc Res 1989;37:77-104. 
73 Jain RK: Transport of molecules in the tumor interstitium: A review. Cancer Res 
 1987;47:3039-3051. 
74 Boucher Y, Salehi H, Witwer B, Harsh GRt, Jain RK: Interstitial fluid pressure in 
 intracranial tumours in patients and in rodents. Br J Cancer 1997;75:829-836. 
75 Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK: Taxane-induced apoptosis 
 decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical 
 implications. Cancer Res 1999;59:3776-3782. 
76 Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ: Role of reoxygenation in 
 induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995;55:3564-
 3568. 
  
85 
 
77 Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells 
 secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 
 1983;219:983-985. 
78 Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization 
 by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient 
 across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-
 3736. 
79 Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani 
 DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, 
 Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain 
 RK: Direct evidence that the vegf-specific antibody bevacizumab has antivascular effects in 
 human rectal cancer. Nat Med 2004;10:145-147. 
80 Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM: Tumor vessel 
 development and maturation impose limits on the effectiveness of anti-vascular therapy. Am 
 J Pathol 2003;162:183-193. 
81 Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both 
 pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 
 2003;111:1287-1295. 
82 Hurst J, Maniar N, Tombarkiewicz J, Lucas F, Roberson C, Steplewski Z, James W, Perras 
 J: A novel model of a metastatic human breast tumour xenograft line. Br J Cancer 
 1993;68:274-276. 
  
86 
 
83 Lev DC, Kiriakova G, Price JE: Selection of more aggressive variants of the gi101a human 
 breast cancer cell line: A model for analyzing the metastatic phenotype of breast cancer. 
 Clin Exp Metastasis 2003;20:515-523. 
84 Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm 
 DL, Price JE: Using a xenograft model of human breast cancer metastasis to find genes 
 associated with clinically aggressive disease. Cancer Res 2005;65:5578-5587. 
85 Ozerdem U, Hargens AR: A simple method for measuring interstitial fluid pressure in 
 cancer tissues. Microvasc Res 2005;70:116-120. 
86 Chelouche-Lev D, Miller CP, Tellez C, Ruiz M, Bar-Eli M, Price JE: Different signalling 
 pathways regulate vegf and il-8 expression in breast cancer: Implications for therapy. Eur J 
 Cancer 2004;40:2509-2518. 
87 Olive PL, Banath JP, Aquino-Parsons C: Measuring hypoxia in solid tumours--is there a 
 gold standard? Acta Oncol 2001;40:917-923. 
88 Tong X, Zhou J, Tan Y: Liquid chromatography/tandem triple-quadrupole mass 
 spectrometry for determination of paclitaxel in rat tissues. Rapid Commun Mass Spectrom 
 2006;20:1905-1912. 
89 Wang X, Pang J, Newman RA, Kerwin SM, Bowman PD, Stavchansky S: Quantitative 
 determination of fluorinated caffeic acid phenethyl ester derivative from rat blood plasma 
 by liquid chromatography-electrospray ionization tandem mass spectrometry. J 
 Chromatogr B Analyt Technol Biomed Life Sci 2008;867:138-143. 
90 Kempen EC, Yang P, Felix E, Madden T, Newman RA: Simultaneous quantification of 
 arachidonic acid metabolites in cultured tumor cells using high-performance liquid 
  
87 
 
 chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 
 2001;297:183-190. 
91 Teicher BA: A systems approach to cancer therapy. (antioncogenics + standard cytotoxics--
 >mechanism(s) of interaction). Cancer Metastasis Rev 1996;15:247-272. 
92 Kasman I, Bagri A, Mak J, Peale F, Carano R, Ross J, Berry L, Shin Y, Rudewicz P, Austin 
 C, Ferrando R, Ross S, Crocker L, Van Bruggen N, Pais H, Scudder K, Hollister B, 
 Plowman G: Mechanistic evaluation of the combination effect of anti-vegf and 
 chemotherapy: AACR Meeting, 2008,  
93 Ferretti S, Allegrini PR, Becquet MM, McSheehy PM: Tumor interstitial fluid pressure as 
 an early-response marker for anticancer therapeutics. Neoplasia 2009;11:874-881. 
94 Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK: Pathology: Cancer 
 cells compress intratumour vessels. Nature 2004;427:695. 
95 Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, Milas L: Effect of 
 docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 
 1999;5:4191-4198. 
96 Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O: Addition of bevacizumab to 
 fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of 
 cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199-205. 
97 Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, 
 Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast 
 cancer. N Engl J Med 2007;357:2666-2676. 
98 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, 
 Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: 
  
88 
 
 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
 N Engl J Med 2004;350:2335-2342. 
99 Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson 
 DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N 
 Engl J Med 2006;355:2542-2550. 
 
  
89 
 
VITA 
 
Ricardo Hugo Alvarez was born in Fray Luis Beltran, Patagonia-Argentina on January 27, 
1964, the son of Fanny D. Roldán J.D. and Ricardo Alvarez, M.D. After completing his work 
at Nicolas Avellaneda High School, Houston, Texas in 1984, she entered Universidad 
Nacional de La Plata in La Plata, Argentina.  He received the degree of Medical Doctor in 
March, 1990. For the next four years, she worked as an Internal Medicine Resident at Centro 
Oncológico de Excelencia, Fundación José Maria Mainetti, Gonnet, Argentina. In 2004 he 
entered The University of Texas at Houston and completed the Internal medicine Residency 
in 2006. In July of 2009, after complete his fellowship in Hematology and Oncology, he 
started as Assistant Professor of Medicine at Breast Medical Oncology Department, MD 
Anderson Cancer Center. In July of 2007 he entered The University of Texas Health Science 
Center at Houston Graduate School of Biomedical Sciences.  
 
 
Permanent address: 
3807 Sun Valley Drive 
Houston, Texas 77025 
  
